You are here: Industry Insights > Merck

News List

EC grants approval to Merck’s pneumonia vaccine for use in adults Pharmaceutical-Technology
December 17, 2021
The European Commission (EC) has granted approval to Merck’s (MSD) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for active immunisation to prevent invasive disease and pneumonia in adults aged 18 years and above.
Merck Announces Additional $150M Investment Through 2025 to Help End Maternal Mortality Inequities AmericanPharmaceuticalReview
December 09, 2021
Merck announced an additional $150 million commitment through Merck for Mothers to further advance the initiative’s mission of helping create a world where no woman has to die giving life. This investment builds on a $500 million commitment made in ...
Merck to Supply Up to 1 Million Courses of Molnupiravir, an Oral Antiviral Medicine for the Treatment of COVID-19, to Canadian Govt AmericanPharmaceuticalReview
December 07, 2021
Merck has entered into a Supply Agreement with the Government of Canada for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of COVID-19. This investigational medicine is being developed by...
NGM Bio Clinical Trial Collaboration with Merck on NGM707, an ILT2/ILT4 Dual Antagonist Antibody, in Combination KEYTRUDA® AmericanPharmaceuticalReview
December 07, 2021
NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and..
Canada enters deals to procure Merck and Pfizer’s Covid-19 antiviral pills Pharmaceutical-Technology
December 07, 2021
The Government of Canada has entered agreements with Merck and Pfizer to procure courses of their Covid-19 oral antiviral pills.
Merck's COVID-19 Pill Appears Effective, but May Pose Pregnancy Risks: FDA Drugs
November 30, 2021
Merck's experimental COVID-19 antiviral pill appears effective, but may pose risks for pregnant women, including birth defects and toxicity to developing fetuses, according to the U.S. Food and Drug Administration.
Molnupiravir: Merck’s Covid-19 antiviral less effective in new analysis Pharmaceutical-Technology
November 30, 2021
Merck has provided updated data on its Covid-19 antiviral, molnupiravir, that shows the antiviral to be significantly less effective against the virus than previously thought.
Merck Provides Update Trial of Once-Weekly Investigational Combination of MK-8507 and Islatravir for HIV-1 Treatment AmericanPharmaceuticalReview
November 24, 2021
Merck announced an update regarding the Phase 2 IMAGINE-DR clinical trial (MK-8507-13), which is evaluating the investigational combination of MK-8507, a non-nucleoside reverse transcriptase inhibitor...
Merck Announces Initiation of Phase 3 Study Evaluating VERQUVO® in Patients with Chronic Heart Failure and Reduced Ejection Fraction Who Have Not Had a Recent Worsening Heart Failure Event AmericanPharmaceuticalReview
November 12, 2021
Merck announced the initiation of VICTOR (vericiguat in adults with Chronic heart failure and Reduced ejection fraction), a pivotal Phase 3 randomized, placebo-controlled cardiovascular clinical trial...
Merck and Ridgeback Announce Japanese Government to Purchase 1.6 Million Courses of Molnupiravir, an Investigational Oral COVID-19 Antiviral Medicine, Upon Authorization or Approval AmericanPharmaceuticalReview
November 12, 2021
Merck and Ridgeback Biotherapeutics announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801)...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page